Abstract
Current therapeutic approaches for cancer rely on the inhibition of mitogenic stimuli. Research conducted in our laboratory has demonstrated that the classic growth factor FGF-2 inhibits the proliferation of malignant cells from the Y1 adrenocortical lineage (Dias et al., 2019). Furthermore, it has been observed that the combination of mitogens with stress pathway inhibitors results in th…